#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15126	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2107	712.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1689	1689	T	830	T,C	768,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15126	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2107	712.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1423	1423	C	926	C	866	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28068	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3546	788.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1615	1615	A	983	A	927	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28068	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3546	788.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2249	2249	C	921	C	835	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28068	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3546	788.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2323	2323	A	896	A	852	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28068	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3546	788.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2875	2875	C	857	C,T	792,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2028	folP	855	855	100.0	folP.l15.c4.ctg.1	1487	135.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1009	1011	AGC	198;196;196	A;G;C	181;181;176	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3258	154.6	1	SNP	p	S91F	1	.	.	271	273	TTC	538	540	TTC	163;160;159	T;T;C	150;145;144	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3258	154.6	1	SNP	p	D95G	1	.	.	283	285	GGC	550	552	GGC	167;169;169	G;G;C	152;154;155	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3258	154.6	1	SNP	p	G95N	0	.	.	283	285	GGC	550	552	GGC	167;169;169	G;G;C	152;154;155	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1804	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1389	129.3	1	SNP	p	G45D	0	.	.	133	135	GGC	535	537	GGC	232;237;236	G;G;C	221;223;221	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1014	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	942	106.7	0	.	n	.	0	A197.	DEL	197	197	A	542	542	A	230	A	212	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1467	1469	GTC	224;224;223	G;T;C	210;208;208	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	1	SNP	p	D86N	0	.	.	256	258	GAC	573	575	GAC	190;188;189	G;A;C	182;176;178	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	1	SNP	p	S87R	1	.	.	259	261	CGT	576	578	CGT	187;186;187	C;G;T	179;178;177	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	1	SNP	p	R87W	0	.	.	259	261	CGT	576	578	CGT	187;186;187	C;G;T	179;178;177	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	1	SNP	p	R87I	0	.	.	259	261	CGT	576	578	CGT	187;186;187	C;G;T	179;178;177	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5174	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2931	176.0	1	SNP	p	S88P	0	.	.	262	264	TCC	579	581	TCC	187;192;197	T;C;C	178;184;188	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4408	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2773	158.6	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1366	1368	TGC	201;202;202	T,C;G,A;C	190,1;192,1;193	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4408	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2773	158.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	204;196;191	G;G;C	187;184;177	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1253	1255	GCA	206;208;213	G;C;A	197;200;204	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1256	1258	ATC	214;218;220	A;T;C	205;208;210	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1268	1270	GTG	219;219;217	G;T;G	209;208;207	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1268	1270	GTG	219;219;217	G;T;G	209;208;207	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1772	1774	ACC	221;220;219	A;C;C	198;201;200	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1826	1828	GCG	196;194;194	G;C,G;G	172;155,1;156	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1826	1828	GCG	196;194;194	G;C,G;G	172;155,1;156	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1949	1951	GGC	194;194;195	G;G;C	183;184;184	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1958	1960	GGC	199;200;202	G,T;G;C	182,1;184;182	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4156	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	174.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1976	1978	TCG	180;180;179	T,G;C;GCCC,GCCCC	128,5;147;153,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5532	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3006	183.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1524	1526	CCG	202;201;203	C;C;G	181;189;185	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2366	porA	1146	1146	99.56	porA.l6.c30.ctg.1	1803	130.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	570	570	C	183	C	166	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	458	460	GAA	226;222;221	G;A;A	218;214;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	746	748	GAT	230;229;231	G,A;A;T	214,1;213;213	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	869	871	TCA	230;229;228	T;C,G;A	213;213,1;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	998	1000	GTC	229;233;233	G,A;T;C,G	217,1;216;217,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1328	1330	GCA	225;225;228	G;C;A	209;209;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	1	SNP	p	G120K	1	.	.	358	360	AAG	704	706	AAG	217;217;217	A;A;G,T	202;202;200,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	1	SNP	p	D121N	0	.	.	361	363	GAC	707	709	GAC	215;215;215	G;A;C	201;201;203	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2874	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1519	187.0	1	SNP	p	A121D	1	.	.	361	363	GAC	707	709	GAC	215;215;215	G;A;C	201;201;203	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11404	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4809	236.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2066	2068	AAT	269;266;264	A;A;T	254;249;249	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1178	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	979	119.6	1	SNP	p	V57M	1	.	.	169	171	ATG	478	480	ATG	234;233;232	A;T;G	216;217;217	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
